RESUMEN
Systemic contact dermatitis (SCD) is a broad category of syndromes characterized by a variety of clinical presentations and offending agents. There exists general consensus that SCD and its subcategories are due to type IV (and less commonly type III) hypersensitivity reactions, in which a previously sensitized individual undergoes a cytotoxic CD8+ T-cell response upon systemic reexposure. There are various linked allergens, generally grouped into plants, foods, metals, and medications. Diagnosis is relatively successful through epicutaneous patch testing utilizing standard series and customized panels. Treatment consists of allergen avoidance diets as determined by clinical history and patch testing.
Asunto(s)
Alérgenos/inmunología , Dermatitis Alérgica por Contacto/diagnóstico , Dermatitis Alérgica por Contacto/inmunología , Dermatitis Atópica/diagnóstico , Dermatitis Atópica/inmunología , Hipersensibilidad a las Drogas/diagnóstico , Hipersensibilidad a las Drogas/inmunología , Humanos , Pruebas del ParcheRESUMEN
The purpose of this study was to investigate the effects of ß-alanine supplementation on a 10 km running time trial and lactate concentration in physically active adults. Sixteen healthy subjects were divided randomly into two groups: ß-alanine (n = 8) and placebo group (n = 8). The experimental group ingested 5 g/day of ß-alanine plus 1 g of resistant starch, and control group ingested 6 g of resistant starch, both for 23 days. Time to complete a 10-km running time trial and lactate concentration following the test were assessed at baseline and post 23 days. The running training program was performed three times per week on non-consecutive days (day 1: running 7 km; day 2: six sprints of 500 m at maximum speed with 2 min of recovery; day 3: running 12 km). The time to complete a 10-km running time trial decreased significantly only for the ß-alanine group (Pre = 3441 ± 326.7, Post = 3209 ± 270.5 s, p < 0.05). When analyzing the delta (Time post minus Time at baseline value) there was a statistically significant difference between the ß-alanine vs placebo group (-168.8 ± 156.6 vs. -53.60 ± 78.81 s, p = 0.007), respectively. In addition, the ß-alanine group presented lower blood lactate concentration after the 10-km test (ß-alanine: Pre = 8.45 ± 1.94 vs. Post = 6.95 ± 2.44 mmol/L; Placebo: Pre = 8.7 ± 3.0 vs. Post = 10.8 ± 2.5 mmol/L, p = 0.03). In conclusion, ß-alanine supplementation improved the 10-km running time trial and reduced lactate concentration in physically active adults.
RESUMEN
OBJECTIVE: With combination-antiretroviral therapy, HIV-infected individuals live longer with an elevated burden of cancer. Given the high prevalence of smoking among HIV-infected populations, we examined the risk of incident cancers attributable to ever smoking cigarettes. DESIGN: Observational cohort of HIV-infected participants with 270â136 person-years of follow-up in the North American AIDS Cohort Collaboration on Research and Design consortium. Among 52â441 participants, 2306 were diagnosed with cancer during 2000-2015. MAIN OUTCOME MEASURES: Estimated hazard ratios and population-attributable fractions (PAF) associated with ever cigarette smoking for all cancers combined, smoking-related cancers, and cancers that were not attributed to smoking. RESULTS: People with cancer were more frequently ever smokers (79%) compared with people without cancer (73%). Adjusting for demographic and clinical factors, cigarette smoking was associated with increased risk of cancer overall [hazard ratiosâ=â1.33 (95% confidence interval: 1.18-1.49)]; smoking-related cancers [hazard ratiosâ=â2.31 (1.80-2.98)]; lung cancer [hazard ratiosâ=â17.80 (5.60-56.63)]; but not nonsmoking-related cancers [hazard ratiosâ=â1.12 (0.98-1.28)]. Adjusted PAFs associated with ever cigarette smoking were as follows: all cancers combined, PAFâ=â19% (95% confidence interval: 13-25%); smoking-related cancers, PAFâ=â50% (39-59%); lung cancer, PAFâ=â94% (82-98%); and nonsmoking-related cancers, PAFâ=â9% (1-16%). CONCLUSION: Among HIV-infected persons, approximately one-fifth of all incident cancer, including half of smoking-related cancer, and 94% of lung cancer diagnoses could potentially be prevented by eliminating cigarette smoking. Cigarette smoking could contribute to some cancers that were classified as nonsmoking-related cancers in this report. Enhanced smoking cessation efforts targeted to HIV-infected individuals are needed.
Asunto(s)
Fumar Cigarrillos/efectos adversos , Infecciones por VIH/complicaciones , Neoplasias/epidemiología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Estudios de Seguimiento , Humanos , Incidencia , Masculino , Persona de Mediana Edad , América del Norte/epidemiología , Prevalencia , Factores de Riesgo , Adulto JovenRESUMEN
BACKGROUND: This study evaluates the benefits of integrating behavioral health and trauma services for Latinas with a history drug use. Changes in quality of life (QOL) domains were documented after participation in a manualized intervention in a cohort of Latinas. METHODS: Participants were part of a prospective cohort study of 136 Latinas with co-occurring disorders (COD) who may have experienced trauma and receiving services in our outpatient treatment facility in Bayamón, Puerto Rico. The WHOQOL-BREF Spanish version was used to score physical, psychological, social, and environmental QOL domains, at intake and after six months. Sociodemographic variables, alcohol, drug use, mental health disorders, and severity of substance use disorders (as defined by the DSM-5) were also tabulated. Descriptive statistics and paired t test or the Wilcoxon signed-rank test were computed for comparison. RESULTS: A median age of 39 years was seen and with 76% high school education or higher degree. The majority were unemployed (95.9%). A diagnosis of severe cocaine use (51.4%) was present and almost half (49.5%) had three or more DSM-5 diagnoses. Mean QOL scores were higher at six months with statistically significant differences in each domain. Women with neurodevelopmental disorders and schizophrenia yielded higher mean QOL scores for each domain at six months except for the social domain. Women with polydrug use and women who reported exposure to trauma and depressive disorder experienced statistically significant increments in the physical, psychological and social domains in comparison to counterpart women. CONCLUSIONS: Significant and positive changes in QOL were found in each domain. Latinas who reported traumatic events had lower scores in the physical and psychological QOL domains. There was a high prevalence of diminished physical and mental functioning in Latinas with COD. The exposure to trauma and the lack of social support negatively affect treatment access and retention for Latinas.
Asunto(s)
Hispánicos o Latinos , Calidad de Vida/psicología , Trastornos por Estrés Postraumático/psicología , Trastornos Relacionados con Sustancias/psicología , Adulto , Femenino , Humanos , Persona de Mediana Edad , Estudios Prospectivos , Puerto Rico , Trastornos por Estrés Postraumático/terapia , Trastornos Relacionados con Sustancias/terapia , Resultado del TratamientoRESUMEN
OBJECTIVE: Late HIV testing (LT), defined as receiving an AIDS diagnosis within a year of one's first positive HIV test, is associated with higher HIV transmission, lower HAART effectiveness, and worse outcomes. Latinos represent 36% of LT in the US, yet research concerning LT among HIV cases in Puerto Rico is scarce. METHODS: Multivariable logistic regression analysis was used to identify factors associated with LT, and a CochranâArmitage test was used to determine LT trends in an HIV-infected cohort followed at a clinic in Puerto Rico specialized in the management and treatment of HIV. RESULTS: From 2000 to 2011, 47% of eligible patients were late testers, with lower median CD4 counts (54 vs. 420 cells/mm3) and higher median HIV viral load counts (253,680 vs. 23,700 copies/mL) than non-LT patients. LT prevalence decreased significantly, from 47% in 2000 to 37% in 2011. In a mutually adjusted logistic regression model, males, older age at enrollment and past history of IDU significantly increased LT odds, whereas having a history of amphetamine use decreased LT odds. When the data were stratified by mode of transmission, it became apparent that only the category men who have sex with men (MSM) saw a significant reduction in the proportion of LT, falling from 67% in 2000 to 33% in 2011. CONCLUSION: These results suggest a gap in early HIV detection in Puerto Rico, a gap that decreased only among MSM. An evaluation of the manner in which current HIV-testing guidelines are implemented on the island is needed.
RESUMEN
The purpose of this manuscript is to assess and compare HIV risk behaviors among early adolescents after a three-year pilot study. A total of 135 public and private junior high schools students completed the intervention protocol. A self-administered questionnaire was given at baseline and at the end of the third year (fourth measure). Descriptive and inferential analyses were performed using SPSS 20.0. About 60% of the students were 14 years old at the fourth measure. The proportion of students that did not report at least one HIV risk behavior at baseline and those that reported any risk behavior at the fourth measure was lower in the intervention group (45.0%) than in the control group (54.5%). The proportion of students that reported at least one HIV risk behavior at baseline and those that did not report any HIV risk behavior at the fourth measure was higher in the intervention group than in the control group (33.3% vs. 8.3%). The proportion of students engaging in HIV risk behaviors was higher in the control group than in the intervention group at the fourth measure, suggesting that A Supportive Model for HIV Risk Reduction in Early Adolescence (ASUMA) intervention might be a promising initiative to reduce adolescents' engagement in HIV risk behaviors.
Asunto(s)
Conducta del Adolescente , Infecciones por VIH/prevención & control , Asunción de Riesgos , Servicios de Salud Escolar , Adolescente , Conducta del Adolescente/etnología , Conducta del Adolescente/psicología , Femenino , Infecciones por VIH/etnología , Infecciones por VIH/psicología , Hispánicos o Latinos , Humanos , Masculino , Evaluación de Resultado en la Atención de Salud , Proyectos Piloto , Estudios Prospectivos , Puerto Rico , Encuestas y CuestionariosRESUMEN
Pancytopenia is seen in late HIV infection; it is associated with medical complications and with decreased survival. We determined the prevalence of pancytopenia at baseline in a cohort of HIV-positive Hispanics living in Puerto Rico, and compared their socio-demographic, immunological and clinical characteristics. A total of 1202 patients enrolled between 2000 and 2010 were included. They were grouped according to pancytopenia status, defined by having: platelets <150,000 µL, white cell count <4000 µL, and hemoglobin <12 g/dL (women) or <13 g/dL (men). Differences were evaluated using Student's t-test, Chi-square test and Kaplan-Meier method. The prevalence of pancytopenia was 8.7%. Patients with pancytopenia had lower BMI and lower CD4 count, as well as higher HIV viral load and higher proportions of unemployment, clinical AIDS and antiretroviral treatment (ART) use (p < 0.05). One-year mortality rate was significantly higher in patients with pancytopenia (18.1% vs. 5.1%, p < 0.001). When stratifying for ART this association persisted for patients who did not receive ART (41.4% vs. 5.2%, p < 0.001), but it was not seen in patients who received treatment (9.2% vs. 5.6%, p = 0.196). Pancytopenia was associated with elements of advanced stages of HIV. ART could reduce the mortality of HIV-patients with pancytopenia to levels comparable to patients without the disorders.
Asunto(s)
Infecciones por VIH/complicaciones , Hispánicos o Latinos , Pancitopenia/etnología , Síndrome de Inmunodeficiencia Adquirida/virología , Adulto , Anciano , Fármacos Anti-VIH/uso terapéutico , Recuento de Linfocito CD4 , Femenino , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/etnología , Infecciones por VIH/mortalidad , Humanos , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Pancitopenia/tratamiento farmacológico , Pancitopenia/mortalidad , Pancitopenia/virología , Prevalencia , Puerto Rico/epidemiología , Carga ViralRESUMEN
OBJECTIVE: Late HIV testing (LT), defined as receiving an AIDS diagnosis within a year of one's first positive HIV test, is associated with higher HIV transmission, lower HAART effectiveness, and worse outcomes. Latinos represent 36% of LT in the US, yet research concerning LT among HIV cases in Puerto Rico is scarce. METHODS: Multivariable logistic regression analysis was used to identify factors associated with LT, and a CochranâArmitage test was used to determine LT trends in an HIV-infected cohort followed at a clinic in Puerto Rico specialized in the management and treatment of HIV. RESULTS: From 2000 to 2011, 47% of eligible patients were late testers, with lower median CD4 counts (54 vs. 420 cells/mm3) and higher median HIV viral load counts (253,680 vs. 23,700 copies/mL) than non-LT patients. LT prevalence decreased significantly, from 47% in 2000 to 37% in 2011. In a mutually adjusted logistic regression model, males, older age at enrollment and past history of IDU significantly increased LT odds, whereas having a history of amphetamine use decreased LT odds. When the data were stratified by mode of transmission, it became apparent that only the category men who have sex with men (MSM) saw a significant reduction in the proportion of LT, falling from 67% in 2000 to 33% in 2011. CONCLUSION: These results suggest a gap in early HIV detection in Puerto Rico, a gap that decreased only among MSM. An evaluation of the manner in which current HIV-testing guidelines are implemented on the island is needed.
Asunto(s)
Síndrome de Inmunodeficiencia Adquirida/diagnóstico , Infecciones por VIH/diagnóstico , Homosexualidad Masculina/estadística & datos numéricos , Adolescente , Adulto , Anciano , Terapia Antirretroviral Altamente Activa/métodos , Estudios de Cohortes , Diagnóstico Tardío , Femenino , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/epidemiología , Humanos , Modelos Logísticos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Prevalencia , Puerto Rico/epidemiología , Factores de Riesgo , Resultado del Tratamiento , Adulto JovenRESUMEN
BACKGROUND: Anemia occurs frequently in HIV-infected patients and has been associated with an increased risk of death in this population. For Hispanic subjects, information describing this blood disorder during HIV is scarce. Therefore, the present study examined data from a cohort of HIV-positive Hispanics to determine the prevalence of anemia, identify its associated factors, and evaluate its relationship with one-year mortality. METHODS: This study included 1,486 patients who enrolled between January, 2000 and December, 2010 in an HIV-cohort in Bayamón, Puerto Rico. Data were collected through personal interviews and medical record abstractions. To determine the factors independently associated with anemia, a multivariable logistic regression model was used. Kaplan-Meier and Cox proportional hazards models were also performed to estimate survival time and to predict death risk. RESULTS: The prevalence of anemia at enrollment was 41.5%. Factors independently associated with increased odds of anemia were: unemployment (OR = 2.02; 95% CI 1.45-2.79), CD4 count <200 cells/µL (OR = 2.66; 95% CI 1.94-3.66), HIV viral load ≥100,000 copies/mL (OR = 1.94; 95% CI 1.36-2.78), white blood cell count <4,000 cells/µL (OR = 2.42; 95% CI 1.78-3.28) and having clinical AIDS (OR = 2.39; 95% CI 1.39-4.09). Overweight (OR = 0.43; 95% CI 0.32-0.59) and obese (OR = 0.44; 95% CI 0.29-0.67) BMI's were independently associated with reduced odds of anemia. Survival differed significantly by anemia status (log-rank test: p < 0.001). One-year mortality estimates were: 30.8%, 23.3%, 8.4% and 2.5%, for patients with severe, moderate, mild and no anemia, respectively. Having anemia at baseline was independently associated with an increased one-year mortality risk (severe anemia: HR = 9.06; 95% CI: 4.16-19.72; moderate anemia: HR = 6.51; 95% CI: 3.25-13.06; mild anemia: HR = 2.53; 95% CI: 1.35-4.74). CONCLUSIONS: A high prevalence of anemia at enrollment was observed in this cohort of HIV-infected Hispanics. Unemployment and several adverse prognostic features of HIV infection were independently associated with this blood disorder. Anemia resulted to be the strongest predictor of one-year mortality, evidencing a dose-response effect. Further investigations are needed to evaluate whether recovering from anemia is associated with longer survival, and to identify the types of anemia affecting this particular group of HIV patients.
Asunto(s)
Anemia/etnología , Infecciones por VIH/enzimología , Hispánicos o Latinos/estadística & datos numéricos , Adulto , Anciano , Anemia/epidemiología , Anemia/mortalidad , Índice de Masa Corporal , Recuento de Linfocito CD4 , Estudios de Cohortes , Comorbilidad , Femenino , Infecciones por VIH/epidemiología , Humanos , Estimación de Kaplan-Meier , Recuento de Leucocitos , Modelos Logísticos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Prevalencia , Modelos de Riesgos Proporcionales , Puerto Rico/epidemiología , Factores de Riesgo , Tasa de Supervivencia , Desempleo/estadística & datos numéricos , Carga Viral , Adulto JovenRESUMEN
PURPOSE: Human immunodeficiency virus (HIV) in the elderly population has serious repercussions. The elderly are underdiagnosed for HIV and the costs associated with their late-stage care represent a financial burden to the public health system. The purpose is to analyze various profiles among a cohort of elderly patients with HIV/AIDS. METHODS: This is a baseline cohort 60 years or older seen in the Retrovirus Research Center between January 2000 to December 2011. We present the profiles of our cohort stratified by gender and body mass index viewed as a covariate of interest. RESULTS: A total of 266 people (68% males and 32% females) seen at the Center were older than 60 years of age. Males were significantly more often overweight (p<.05). Females were significantly more underweight with chronic conditions (p<.05). Women had higher CD4 count and lower HIV viral loads (p<.05). Underweight elderly males were more heavily affected with the burden of HIV infection compared with women.
Asunto(s)
Índice de Masa Corporal , Recuento de Linfocito CD4 , Infecciones por VIH/inmunología , Carga Viral , Anciano , Estudios de Cohortes , Femenino , Infecciones por VIH/epidemiología , Hispánicos o Latinos , Humanos , Masculino , Persona de Mediana Edad , Puerto Rico/epidemiología , Factores SexualesRESUMEN
OBJECTIVE: Evaluating the effectiveness of antiretroviral therapy in a sample of Colombian patients diagnosed as having HIV/AIDS and being treated by the Colombian Health Social Security System (CHSSS) METHODS: A descriptive study was conducted among 134 HIV/AIDS patients of any age or gender who had received antiretroviral therapy in the cities of Pereira and Manizales between July 1st 2008 and June 30th 2009. The following factors were assessed from the clinical history of the patients seen in three health insurance companies: viral load, CD4 count, antiretroviral treatment regimens, prescribed daily doses of medications, length of disease evolution, duration of therapy, history of opportunistic diseases, and drug costs. RESULTS: There was male predominance (91 men cf 43 women), mean age beingf 39 years, and an average of 59 months since diagnosis. All treatment regimens were defined by each drug's defined daily dose (DDD). The therapy was effective in 74.5 % of patients. Effectiveness was defined as being viral load < 400 copies/ml. About 79.1 % of patients had had their viral load measured during the last 6 months. Non-adherence to treatment and a history of having acquired 2 other sexually- transmitted infections were associated with an increased risk of uncontrolled HIV infection. The average value of drugs per year per patient was $4,077.2 ± 3,043.8 U.S. dollars/year. CONCLUSIONS: Non-adherence to treatment remains one of the most important issues regarding antiretroviral therapy effectiveness, so programmes intended to control HIV/AIDS must address this problem.
Asunto(s)
Fármacos Anti-VIH/uso terapéutico , Infecciones por VIH/tratamiento farmacológico , Infecciones Oportunistas Relacionadas con el SIDA/economía , Infecciones Oportunistas Relacionadas con el SIDA/epidemiología , Adulto , Fármacos Anti-VIH/economía , Terapia Antirretroviral Altamente Activa , Recuento de Linfocito CD4 , Colombia/epidemiología , Costos de los Medicamentos , Femenino , Infecciones por VIH/economía , Infecciones por VIH/epidemiología , Gastos en Salud , Humanos , Masculino , Cumplimiento de la Medicación , Persona de Mediana Edad , Enfermedades de Transmisión Sexual/epidemiología , Resultado del Tratamiento , Población Urbana , Carga ViralRESUMEN
Objective Evaluating the effectiveness of antiretroviral therapy in a sample of Colombian patients diagnosed as having HIV/AIDS and being treated by the Colombian Health Social Security System (CHSSS) Methods A descriptive study was conducted among 134 HIV/AIDS patients of any age or gender who had received antiretroviral therapy in the cities of Pereira and Manizales between July 1st 2008 and June 30th 2009. The following factors were assessed from the clinical history of the patients seen in three health insurance companies: viral load, CD4 count, antiretroviral treatment regimens, prescribed daily doses of medications, length of disease evolution, duration of therapy, history of opportunistic diseases, and drug costs. Results There was male predominance (91 men cf 43 women), mean age beingf 39 years, and an average of 59 months since diagnosis. All treatment regimens were defined by each drug's defined daily dose (DDD). The therapy was effective in 74.5 percent of patients. Effectiveness was defined as being viral load < 400 copies/ml. About 79.1 percent of patients had had their viral load measured during the last 6 months. Non-adherence to treatment and a history of having acquired 2 other sexually- transmitted infections were associated with an increased risk of uncontrolled HIV infection. The average value of drugs per year per patient was $4,077.2 ± 3,043.8 U.S. dollars/year. Conclusions Non-adherence to treatment remains one of the most important issues regarding antiretroviral therapy effectiveness, so programmes intended to control HIV/AIDS must address this problem.
Objetivo Evaluar la efectividad del tratamiento antirretroviral en una muestra de pacientes con diagnóstico de VIH/SIDA en dos ciudades colombianas. Métodos Estudio descriptivo en 134 pacientes en tratamiento para VIH/SIDA de cualquier edad y género en Pereira y Manizales entre 1 de julio de 2008 y 30 de junio de 2009. Se evaluó: carga viral, conteo de linfocitos CD4, esquemas antirretrovirales, dosis diaria prescrita, tiempo evolución de enfermedad, duración de terapia, antecedentes de enfermedades oportunistas, costos de medicamentos. Resultados Predominio masculino (91 hombres vs 43 mujeres), promedio de edad: 39 años y 59 meses de evolución de la enfermedad. Todos recibían esquemas a Dosis Diarias Definidas recomendadas. La terapia era efectiva en 73,6 por ciento de los pacientes (carga viral <400 copias/ml). Se pudo establecer que la falta de adherencia al tratamiento y el antecedente de haber tenido otras 2 infecciones de transmisión sexual se asociaban con mayor riesgo de no controlar la infección por VIH. El valor promedio de los medicamentos por año por paciente fue de US$ 4 077.2 ± 3 043.8 dólares. Conclusiones La falta de adherencia al tratamiento sigue siendo uno de los problemas más importantes para garantizar efectividad, por lo cual los programas de control del VIH/SIDA deben asegurarla.
Asunto(s)
Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Fármacos Anti-VIH/uso terapéutico , Infecciones por VIH/tratamiento farmacológico , Infecciones Oportunistas Relacionadas con el SIDA/economía , Infecciones Oportunistas Relacionadas con el SIDA/epidemiología , Fármacos Anti-VIH/economía , Terapia Antirretroviral Altamente Activa , Colombia/epidemiología , Costos de los Medicamentos , Infecciones por VIH/economía , Infecciones por VIH/epidemiología , Gastos en Salud , Cumplimiento de la Medicación , Enfermedades de Transmisión Sexual/epidemiología , Resultado del Tratamiento , Población Urbana , Carga ViralRESUMEN
Highly active antiretroviral therapy (HAART) significantly reduced the toxoplasmic encephalitis (TE) incidence in acquired immunodeficiency syndrome (AIDS) patients. The TE incidence and mortality were evaluated in an AIDS cohort followed in Puerto Rico before, during, and after HAART implementation in the Island. Of the 2,431 AIDS studied patients 10.9% had TE diagnosis, with an incidence density that decreased from 5.9/100 person-years to 1.1/100 person-years after HAART. Cox proportional hazard analysis showed substantial mortality reduction among TE cases who received HAART. No mortality reduction was seen in those cases who received TE prophylaxis. Although this study shows a TE incidence and mortality reduction in the AIDS cohort after HAART, the incidence was higher than those reported in the United States AIDS patients. Poor TE prophylaxis compliance might explain the lack of impact of this intervention. Strengthening the diagnostic and opportune TE diagnosis and prompt initiation of HAART in susceptible patients is important to control this opportunistic infection.
Asunto(s)
Infecciones Oportunistas Relacionadas con el SIDA/complicaciones , Síndrome de Inmunodeficiencia Adquirida/tratamiento farmacológico , Terapia Antirretroviral Altamente Activa , Toxoplasmosis Cerebral/prevención & control , Adulto , Estudios de Cohortes , Femenino , Humanos , Masculino , Cooperación del Paciente , Puerto Rico/epidemiología , Toxoplasmosis Cerebral/complicaciones , Toxoplasmosis Cerebral/mortalidadRESUMEN
INTRODUCTION: Teenagers are the fastest growing group of newly HIV-infected persons. Consequently, a support model for HIV risk reduction was designed and implemented for early adolescents in Puerto Rico. OBJECTIVE: The purpose of this article is to assess changes in developmental factors and HIV risk behaviors among early adolescents after three years of follow-up of an intervention and a non-intervention group. METHODS: This prospective cohort study followed 135 early adolescents who were enrolled in the ASUMA (A Supportive Model for HIV Risk Reduction in Early Adolescents) Project. The study was performed in two public and two private junior schools. Baseline and three follow-up self-administered questionnaires were given. We examined sociodemographic factors, HIV risk behavior and developmental factors. RESULTS: 48% were in the intervention group and 51.1% were controls. Most adolescents were aged 12 years; 47.4% were males; 75.6% reported not having risk behaviors and 24.4% reported having risk behaviors at anytime in their lifespan. A significant decrease in the HIV risk behaviors median was observed among the intervention group (P < .05), while a nonsignificant increase was found among adolescents in the control group. At the end of the implementation phase, positive improvement in the developmental factors were observed in the intervention group (P < .05). CONCLUSIONS: Our study suggests that the ASUMA project curriculum had a positive effect on developmental factors and HIV risk behaviors, as proposed in our conceptual framework. Also, this study illustrates the importance of the creation of culturally appropriate instruments and interventions to reach the goal of HIV/AIDS reduction.
Asunto(s)
Infecciones por VIH/epidemiología , Infecciones por VIH/prevención & control , Asunción de Riesgos , Adaptación Psicológica , Adolescente , Conducta del Adolescente , Femenino , Conocimientos, Actitudes y Práctica en Salud , Humanos , Masculino , Proyectos Piloto , Estudios Prospectivos , Puerto Rico/epidemiologíaRESUMEN
Objetivo La utilización de antibióticos ha sido objeto de abuso y se relaciona con el desarrollo de grave resistencia bacteriana.Analizar la dispensación de antibióticos de uso sistémico a nivel ambulatorio en una población colombiana entre enero de 2005 y diciembre de 2006 y la valoración de su costo económico. Métodos Estudio observacional descriptivo sobre utilización de antibióticos a partir de prescripciones dispensadas a la totalidad de usuarios que hayan recibido algún antibiótico en 10 ciudades colombianas. Se determinó dosis definida por 1 000 habitantes y día y el costo por 1 000 habitantes y día. Se analizaron las asociaciones de antibióticos empleadas comúnmente. Resultados La dosis diaria definida fue de 1,58 por 1 000 habitantes y día. Los antibióticos más dispensados fueron las penicilinas (amoxicilina dicloxacilina), seguidos de cefalosporinas de primera generación y sulfonamidas. El uso de antibióticos en presentación inyectable fue del 10,4 por ciento y 9,3 por ciento para los años 2005 y 2006 respectivamente. En 11,0 por ciento de los casos se empleó una asociación de antibióticos. El costo total de dispensación de antibióticos fue de $ 4 356 294 644 pesos (US $ 1 708 350) y el coste por mil habitantes y día de $ 3 114 pesos (US $ 1,13) en 2005 y de $ 2 564 pesos (US $ 1,00) en 2006. Discusión Las dosis diarias definidas por mil habitantes y día y el costo de los antibióticos por mil habitantes y día son menores a los reportados en otros países.
Objectives Analysing how systemic antibiotic agents were dispensed to outpatients in a Colombian population between January 2005 and December 2006 and assessing their economic cost as antibiotic use and abuse have been related to serious bacterial resistance. Methods This was a descriptive observational study of antibiotic drug use; a database was compiled from medication usage records maintained by dispensing pharmacies in 10 Colombian cities regarding the total of users who had received some type of antibiotic. The defined daily dose (DDD) and cost per 1,000 inhabitants/day were assessed. The commonly used antibiotic associations were analysed. Results DDD was 1.58 per 1,000 inhabitants per day. The antibiotics most frequently prescribed were penicillin (amoxiciline; dicloxaciline), followed by first-generation cephalosporines and sulphonamides. Injectable antibiotic use was 10.4 percent in 2005 and 9.3 percent in 2006; an association of anti-bacterial agents was used for 11 percent of the patients. Total antibiotic dispensation cost in 2005 was US$ 1,708,350 and cost per 1,000 inhabitants per day was US$ 1.13 in 2005 and US$ 1 in 2006. Conclusions DDD per 1,000 inhabitants per day and cost per inhabitant per day was low compared to other countries.
Asunto(s)
Humanos , Antibacterianos/uso terapéutico , Pacientes Ambulatorios , Antibacterianos/administración & dosificación , Antibacterianos/economía , Colombia , Costos y Análisis de Costo , Prescripciones de Medicamentos/economía , Prescripciones de Medicamentos/estadística & datos numéricosRESUMEN
OBJECTIVES: Analysing how systemic antibiotic agents were dispensed to outpatients in a Colombian population between January 2005 and December 2006 and assessing their economic cost as antibiotic use and abuse have been related to serious bacterial resistance. METHODS: This was a descriptive observational study of antibiotic drug use; a database was compiled from medication usage records maintained by dispensing pharmacies in 10 Colombian cities regarding the total of users who had received some type of antibiotic. The defined daily dose (DDD) and cost per 1,000 inhabitants/day were assessed. The commonly used antibiotic associations were analysed. RESULTS: DDD was 1.58 per 1,000 inhabitants per day. The antibiotics most frequently prescribed were penicillin (amoxiciline; dicloxaciline), followed by first-generation cephalosporines and sulphonamides. Injectable antibiotic use was 10.4 % in 2005 and 9.3 % in 2006; an association of anti-bacterial agents was used for 11 % of the patients. Total antibiotic dispensation cost in 2005 was US$ 1,708,350 and cost per 1,000 inhabitants per day was US$ 1.13 in 2005 and US$ 1 in 2006. CONCLUSIONS: DDD per 1,000 inhabitants per day and cost per inhabitant per day was low compared to other countries.
Asunto(s)
Antibacterianos/uso terapéutico , Pacientes Ambulatorios , Antibacterianos/administración & dosificación , Antibacterianos/economía , Colombia , Costos y Análisis de Costo , Prescripciones de Medicamentos/economía , Prescripciones de Medicamentos/estadística & datos numéricos , HumanosRESUMEN
BACKGROUND: Early initiation of injection drug use (IDU) increases the risk of HIV infection. METHODS: We compare the sociodemographic, psychosocial, and clinical profiles of HIV-positive IDU patients according to the age at which IDU was initiated. This is a cross-sectional study of 1308 patients seen from 1992 through 2005. We compared the profile of patients with early (age < 13 years) vs non-early (age > 13 years) initiation of IDU. The Fisher and chi2 differences in proportions were performed to assess difference among study groups with earlier IDU. The Mantel-Haenszel test was used to calculate the odds ratio. The Kaplan-Meier and log rank tests were used to assess the median survival. Differences were considered significant at alpha = .05. RESULTS: Early initiation of IDU was reported in 11% of our sample. The early initiation group was more likely to smoke tobacco, use alcohol, attempt suicide, have a history of incarceration, have economic problems, and have episodes of anxiety, confusion, depression, excitation, impulsivity, and violence (P < .05). The general survival time of patients was 36.9 months (95% confidence interval 31.9-42.0). A higher prevalence of candidial esophagitis and Pneumocystis jirovecii pneumonia and a lower prevalence of hepatitis C virus coinfection were seen in the early initiation group (P < .05). No differences in mortality, use of antiretroviral therapy, or CD4 T-cell count were seen. CONCLUSIONS: Differences in terms of lifestyle, stress factors, and history of psychological events were seen in the group of patients with early initiation of IDU seen in our facilities. Differences in the clinical scenario were documented.